{"id":42244,"date":"2025-09-25T14:00:33","date_gmt":"2025-09-25T06:00:33","guid":{"rendered":"https:\/\/flcube.com\/?p=42244"},"modified":"2025-09-25T14:00:34","modified_gmt":"2025-09-25T06:00:34","slug":"fosun-kairos-secures-nmpa-approval-for-second-car%e2%80%91t-product-fkc889-targeting-relapsed-refractory-b%e2%80%91cell-all","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=42244","title":{"rendered":"Fosun Kairos Secures NMPA Approval for Second CAR\u2011T Product, FKC889, Targeting Relapsed\/Refractory B\u2011Cell ALL"},"content":{"rendered":"\n<p><strong>Fosun Kairos<\/strong>, a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (<a href=\"https:\/\/www.google.com\/finance\/quote\/600196:SHA\">SHA: 600196<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/2196:HKG\">HKG: 2196<\/a>), announced today that the China National Medical Products Administration (NMPA) has accepted the marketing application for its second CAR\u2011T therapy, <strong>brexucabtagene autoleucel (FKC889)<\/strong>. The product is indicated for adult patients with relapsed or refractory precursor B\u2011cell acute lymphoblastic leukemia (ALL).<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-key-highlights\">Key Highlights<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Domestic Production<\/strong> \u2013 FKC889 is a CD19\u2011targeted CAR\u2011T cell therapy manufactured locally in Mainland China, Hong Kong and Macau via technology transfer and licensing from <strong>Kite\u202fPharma, Inc.<\/strong>, a Gilead Sciences subsidiary.<\/li>\n\n\n\n<li><strong>Regulatory Milestone<\/strong> \u2013 NMPA approval places Fosun Kairos among the few Chinese companies capable of delivering a fully regulated, high\u2011complexity cell therapy within its borders.<\/li>\n\n\n\n<li><strong>Market Context<\/strong> \u2013 The global CAR\u2011T market is projected to exceed <strong>$10\u202fbillion<\/strong> by 2027, with China expected to capture 25\u201130\u202f% of sales as domestic manufacturing and reimbursement frameworks mature.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-clinical-positioning\">Clinical Positioning<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Indication<\/strong><\/td><td>Adult relapsed\/refractory precursor B\u2011cell ALL<\/td><\/tr><tr><td><strong>Reference Product<\/strong><\/td><td>Tecartus (Kite\u202fPharma) \u2013 approved in the U.S. (Jul\u202f2020) and EU (Dec\u202f2020)<\/td><\/tr><tr><td><strong>Bridge Trials<\/strong><\/td><td>Ongoing trials for relapsed\/refractory mantle cell lymphoma (r\/r\u202fMCL) with \u2265\u202f2 prior lines of therapy<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First\u2011Mover Advantage<\/strong> \u2013 By leveraging a proven Kite platform and local manufacturing, Fosun Kairos can reduce supply\u2011chain risk and potentially lower costs for Chinese patients.<\/li>\n\n\n\n<li><strong>Reimbursement Pathway<\/strong> \u2013 NMPA approval is a prerequisite for inclusion in China\u2019s national health insurance schemes, which could accelerate patient access and generate revenue streams.<\/li>\n\n\n\n<li><strong>Expansion Potential<\/strong> \u2013 Success in ALL may pave the way for FKC889\u2019s indication expansion into MCL, solidifying Fosun Kairos\u2019 position as a leading domestic CAR\u2011T developer.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/li>\n<\/ul>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2025092400785_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025092400785_c.\"><\/object><a id=\"wp-block-file--media-b2ba6cd2-4529-483d-ae4f-c079d83b01ba\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2025092400785_c.pdf\">2025092400785_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2025092400785_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-b2ba6cd2-4529-483d-ae4f-c079d83b01ba\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Fosun Kairos, a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196),&#8230;<\/p>\n","protected":false},"author":1,"featured_media":42247,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[21,4370,893,38,892],"class_list":["post-42244","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-car-t","tag-fosun-kairos","tag-hkg-2196","tag-market-approval-filings","tag-sha-600196"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Fosun Kairos Secures NMPA Approval for Second CAR\u2011T Product, FKC889, Targeting Relapsed\/Refractory B\u2011Cell ALL - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Fosun Kairos, a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196), announced today that the China National Medical Products Administration (NMPA) has accepted the marketing application for its second CAR\u2011T therapy, brexucabtagene autoleucel (FKC889). The product is indicated for adult patients with relapsed or refractory precursor B\u2011cell acute lymphoblastic leukemia (ALL).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=42244\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fosun Kairos Secures NMPA Approval for Second CAR\u2011T Product, FKC889, Targeting Relapsed\/Refractory B\u2011Cell ALL\" \/>\n<meta property=\"og:description\" content=\"Fosun Kairos, a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196), announced today that the China National Medical Products Administration (NMPA) has accepted the marketing application for its second CAR\u2011T therapy, brexucabtagene autoleucel (FKC889). The product is indicated for adult patients with relapsed or refractory precursor B\u2011cell acute lymphoblastic leukemia (ALL).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=42244\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-25T06:00:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-25T06:00:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2507.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42244#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42244\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Fosun Kairos Secures NMPA Approval for Second CAR\u2011T Product, FKC889, Targeting Relapsed\\\/Refractory B\u2011Cell ALL\",\"datePublished\":\"2025-09-25T06:00:33+00:00\",\"dateModified\":\"2025-09-25T06:00:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42244\"},\"wordCount\":289,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42244#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2507.webp\",\"keywords\":[\"CAR-T\",\"Fosun Kairos\",\"HKG: 2196\",\"Market approval filings\",\"SHA: 600196\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=42244#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42244\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=42244\",\"name\":\"Fosun Kairos Secures NMPA Approval for Second CAR\u2011T Product, FKC889, Targeting Relapsed\\\/Refractory B\u2011Cell ALL - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42244#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42244#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2507.webp\",\"datePublished\":\"2025-09-25T06:00:33+00:00\",\"dateModified\":\"2025-09-25T06:00:34+00:00\",\"description\":\"Fosun Kairos, a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196), announced today that the China National Medical Products Administration (NMPA) has accepted the marketing application for its second CAR\u2011T therapy, brexucabtagene autoleucel (FKC889). The product is indicated for adult patients with relapsed or refractory precursor B\u2011cell acute lymphoblastic leukemia (ALL).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42244#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=42244\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42244#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2507.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2507.webp\",\"width\":1080,\"height\":608,\"caption\":\"Fosun Kairos Secures NMPA Approval for Second CAR\u2011T Product, FKC889, Targeting Relapsed\\\/Refractory B\u2011Cell ALL\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42244#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Fosun Kairos Secures NMPA Approval for Second CAR\u2011T Product, FKC889, Targeting Relapsed\\\/Refractory B\u2011Cell ALL\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Fosun Kairos Secures NMPA Approval for Second CAR\u2011T Product, FKC889, Targeting Relapsed\/Refractory B\u2011Cell ALL - Insight, China&#039;s Pharmaceutical Industry","description":"Fosun Kairos, a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196), announced today that the China National Medical Products Administration (NMPA) has accepted the marketing application for its second CAR\u2011T therapy, brexucabtagene autoleucel (FKC889). The product is indicated for adult patients with relapsed or refractory precursor B\u2011cell acute lymphoblastic leukemia (ALL).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=42244","og_locale":"en_US","og_type":"article","og_title":"Fosun Kairos Secures NMPA Approval for Second CAR\u2011T Product, FKC889, Targeting Relapsed\/Refractory B\u2011Cell ALL","og_description":"Fosun Kairos, a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196), announced today that the China National Medical Products Administration (NMPA) has accepted the marketing application for its second CAR\u2011T therapy, brexucabtagene autoleucel (FKC889). The product is indicated for adult patients with relapsed or refractory precursor B\u2011cell acute lymphoblastic leukemia (ALL).","og_url":"https:\/\/flcube.com\/?p=42244","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-25T06:00:33+00:00","article_modified_time":"2025-09-25T06:00:34+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2507.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=42244#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=42244"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Fosun Kairos Secures NMPA Approval for Second CAR\u2011T Product, FKC889, Targeting Relapsed\/Refractory B\u2011Cell ALL","datePublished":"2025-09-25T06:00:33+00:00","dateModified":"2025-09-25T06:00:34+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=42244"},"wordCount":289,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=42244#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2507.webp","keywords":["CAR-T","Fosun Kairos","HKG: 2196","Market approval filings","SHA: 600196"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=42244#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=42244","url":"https:\/\/flcube.com\/?p=42244","name":"Fosun Kairos Secures NMPA Approval for Second CAR\u2011T Product, FKC889, Targeting Relapsed\/Refractory B\u2011Cell ALL - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=42244#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=42244#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2507.webp","datePublished":"2025-09-25T06:00:33+00:00","dateModified":"2025-09-25T06:00:34+00:00","description":"Fosun Kairos, a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196), announced today that the China National Medical Products Administration (NMPA) has accepted the marketing application for its second CAR\u2011T therapy, brexucabtagene autoleucel (FKC889). The product is indicated for adult patients with relapsed or refractory precursor B\u2011cell acute lymphoblastic leukemia (ALL).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=42244#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=42244"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=42244#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2507.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2507.webp","width":1080,"height":608,"caption":"Fosun Kairos Secures NMPA Approval for Second CAR\u2011T Product, FKC889, Targeting Relapsed\/Refractory B\u2011Cell ALL"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=42244#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Fosun Kairos Secures NMPA Approval for Second CAR\u2011T Product, FKC889, Targeting Relapsed\/Refractory B\u2011Cell ALL"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2507.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/42244","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=42244"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/42244\/revisions"}],"predecessor-version":[{"id":42248,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/42244\/revisions\/42248"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/42247"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=42244"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=42244"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=42244"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}